Debanjan Ray
Vorstandsvorsitzender bei Synthekine, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Mardi Dier | F | 60 |
Synthekine, Inc.
 Synthekine, Inc. BiotechnologyHealth Technology Synthekine, Inc. engages as a biotechnology company. The company is headquartered in Menlo Park, CA. | 18 Jahre |
| Rachel Humphrey | M | 62 |
CytomX Therapeutics Holdings LLC
 CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA.
Normunity, Inc.
 Normunity, Inc. Miscellaneous Commercial ServicesCommercial Services Normunity, Inc. is a biotechnology company that creates precision immuno-oncology medicines called immune normalizers. The company is based in West Haven, CT and has subsidiaries in the United States. These medicines target novel mechanisms that free the body's normal immunity against cancer. Normunity is based on an ongoing academic-biotech partnership with the lab of Dr. Lieping Chen at Yale School of Medicine. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer. The CEO of the company is Rachel W. Humphrey. | 5 Jahre |
| Timothy Kutzkey | M | 49 |
Synthekine, Inc.
Synthekine, Inc. BiotechnologyHealth Technology Synthekine, Inc. engages as a biotechnology company. The company is headquartered in Menlo Park, CA. | - |
| Robin Knifsend | F | 55 |
Synthekine, Inc.
Synthekine, Inc. BiotechnologyHealth Technology Synthekine, Inc. engages as a biotechnology company. The company is headquartered in Menlo Park, CA. | 3 Jahre |
| Elaine Jones | M | 69 | 8 Jahre | |
| Sean McCarthy | M | 57 |
CytomX Therapeutics Holdings LLC
CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA. | 14 Jahre |
| Lloyd Rowland | M | 67 | 6 Jahre | |
| Frederick Gluck | M | 88 |
CytomX Therapeutics Holdings LLC
CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA. | 16 Jahre |
| Neil Exter | M | 65 |
CytomX Therapeutics Holdings LLC
CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA. | 14 Jahre |
| Marcia Belvin | M | 57 | 6 Jahre | |
| Matthew Young | M | 54 | 9 Jahre | |
| K. Christopher Garcia | M | - |
Synthekine, Inc.
Synthekine, Inc. BiotechnologyHealth Technology Synthekine, Inc. engages as a biotechnology company. The company is headquartered in Menlo Park, CA. | - |
| Olga Granaturova | F | - |
Normunity, Inc.
Normunity, Inc. Miscellaneous Commercial ServicesCommercial Services Normunity, Inc. is a biotechnology company that creates precision immuno-oncology medicines called immune normalizers. The company is based in West Haven, CT and has subsidiaries in the United States. These medicines target novel mechanisms that free the body's normal immunity against cancer. Normunity is based on an ongoing academic-biotech partnership with the lab of Dr. Lieping Chen at Yale School of Medicine. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer. The CEO of the company is Rachel W. Humphrey. | - |
| Nils Lonberg | M | 68 |
Synthekine, Inc.
Synthekine, Inc. BiotechnologyHealth Technology Synthekine, Inc. engages as a biotechnology company. The company is headquartered in Menlo Park, CA. | - |
| Alan Heeger | M | - |
CytomX Therapeutics Holdings LLC
CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA. | - |
| Charles Homcy | M | 75 |
CytomX Therapeutics Holdings LLC
CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA. | 14 Jahre |
| James Meyers | M | 59 | 6 Jahre | |
| Lie Ping Chen | M | - |
Normunity, Inc.
Normunity, Inc. Miscellaneous Commercial ServicesCommercial Services Normunity, Inc. is a biotechnology company that creates precision immuno-oncology medicines called immune normalizers. The company is based in West Haven, CT and has subsidiaries in the United States. These medicines target novel mechanisms that free the body's normal immunity against cancer. Normunity is based on an ongoing academic-biotech partnership with the lab of Dr. Lieping Chen at Yale School of Medicine. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer. The CEO of the company is Rachel W. Humphrey. | - |
| Srini Akkaraju Akkaraju | M | 56 |
Synthekine, Inc.
Synthekine, Inc. BiotechnologyHealth Technology Synthekine, Inc. engages as a biotechnology company. The company is headquartered in Menlo Park, CA. | - |
| Julie Grant | F | 41 |
Synthekine, Inc.
Synthekine, Inc. BiotechnologyHealth Technology Synthekine, Inc. engages as a biotechnology company. The company is headquartered in Menlo Park, CA. | 5 Jahre |
| Danielle Olander | F | - | 10 Jahre | |
| Naiyer Rizvi | M | 60 |
Synthekine, Inc.
Synthekine, Inc. BiotechnologyHealth Technology Synthekine, Inc. engages as a biotechnology company. The company is headquartered in Menlo Park, CA. | 3 Jahre |
| Pablo Cagnoni | M | 60 |
Synthekine, Inc.
Synthekine, Inc. BiotechnologyHealth Technology Synthekine, Inc. engages as a biotechnology company. The company is headquartered in Menlo Park, CA. | 3 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| William Lis | M | 59 | 10 Jahre | |
| V. Lawlis | M | 72 |
Itero Biopharmaceuticals, Inc.
 Itero Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Itero Biopharmaceuticals, Inc. develops biopharmaceutical products for novel therapeutic proteins and antibodies. The firm focuses on the development and commercialization of protein therapeutics that offer significant clinical and commercial advantages over marketed alternatives. It provides recombinant follicle stimulating hormone for the treatment of female infertility. The company was founded in 2006 by Dr. V. Bryan Lawlis Jr., Dr. Darlene P. Horton and Roy Jerald Beers and is headquartered in Mountain View, CA. | 4 Jahre |
| Ho Young Huh | M | 54 |
CytomX Therapeutics Holdings LLC
CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA. | 7 Jahre |
| Timothy Shannon | M | 65 | 5 Jahre | |
| Robert Scarborough | M | - | 3 Jahre | |
| Justin Sapolsky | M | - |
The Wharton School of the University of Pennsylvania
| 10 Jahre |
| Jordan Moelis | M | - |
The Wharton School of the University of Pennsylvania
| 5 Jahre |
| Bryan Irving | M | 60 |
CytomX Therapeutics Holdings LLC
CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA. | 4 Jahre |
| Marion McCourt | F | 64 | 1 Jahre | |
| Emily Janvey | M | - |
The Wharton School of the University of Pennsylvania
| 5 Jahre |
| Charles S. Fuchs | M | 63 | - | |
| Amanuel M. Lakew | M | - |
The Wharton School of the University of Pennsylvania
| 13 Jahre |
| Raakhe Kapoor Tandon | F | - |
The Wharton School of the University of Pennsylvania
| 5 Jahre |
| Eli Simon | M | - |
The Wharton School of the University of Pennsylvania
| 5 Jahre |
| Krishna R. Polu | M | 50 |
CytomX Therapeutics Holdings LLC
CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA. | 1 Jahre |
| Steven Finn | M | 38 |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
| Nicolas Rodriguez-Brizuela | M | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Gene Yoon | M | 49 |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Gary L. Wilcox | M | 77 |
CytomX Therapeutics Holdings LLC
CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA. | - |
| Peggy Phillips | F | 70 | 7 Jahre | |
| John Scarlett | M | 73 | 6 Jahre | |
| Henry Ward Wolff | M | 75 | 13 Jahre | |
| Liam Localio | M | - |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
| Eric VandeVorde | M | - |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
| Teresa Y. Baik | F | - |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
| Matthew Cohen | M | - |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
| Casey Anderson | M | - |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
| Emily Zovko | F | - |
The Wharton School of the University of Pennsylvania
| 14 Jahre |
| Gregory K. Chow | M | 51 |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Ariel Garcia | M | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Xan Magnisalis | M | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Caroline Jones | F | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Angela Simonton | F | - |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
| Sonika Chandra | F | 50 |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| John Riady | M | 38 |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Bob Lonergan | M | - |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
| Amanda Terry | F | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Alex Mitchell | M | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Jian Feng Yu | M | 41 |
The Wharton School of the University of Pennsylvania
| 3 Jahre |
| Nimit Shah | M | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Philippe Audi | M | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Evaristus Tolulope Sokenu | M | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Su-Jin Lim | F | - |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
| Jason Todd Benowitz | M | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Kevin | M | - |
The Wharton School of the University of Pennsylvania
| 5 Jahre |
| Peter Notz | M | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Adam Weitzman | M | 39 |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
| Joshua Beer | M | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Celia Huey | F | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Assaf Harel | M | 51 |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Sandeep Murthy | M | 47 |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Christopher Fortune | M | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| David E. Kirshenbaum | M | - |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
| Andrew Hertzmark | M | 48 |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Jeff Campbell | M | - |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
| Lucius Taylor | M | 49 |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Mahmoud Sharaf | M | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Bikram Bakshi | M | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Jason David Stipanov | M | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Jonathan Stern | M | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Vikram Doshetty | M | - |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
| Natasha Li | F | - |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
| Benjamin Daverman | M | 46 |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Christina Scalzo | F | - |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
| Rami Elghandour | M | 45 |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Gregory Mazlin | M | - |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
| Jason Park | M | 47 |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Bruno del Ama | M | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Alex Verba | M | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| David Howard Way | M | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Farrah Holder | F | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| James Helwig | M | - |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
| Preeti Chadha Doshi | F | - |
The Wharton School of the University of Pennsylvania
| 2 Jahre |
| Lavanya Ashok | F | - |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
| Bill Kirk | M | - |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
| Kim Eddie /barclays/ | - | - |
The Wharton School of the University of Pennsylvania
| 4 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 99 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Debanjan Ray
- Persönliches Netzwerk
